Last reviewed · How we verify
NCT04691674
Optimal Placement Duration of Pancreatic Duct Stent
NA trial testing Endoscopy in Cholangitis in 122 participants. Completed in 31 August 2024.
31 July 2024
Quick facts
| Lead sponsor | DongGuk University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 122 |
| Start date | 1 February 2021 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Endoscopy
Conditions studied
- Cholangitis — all drugs for Cholangitis →
- Post-ERCP Acute Pancreatitis — all drugs for Post-ERCP Acute Pancreatitis →
- Stent Dislodgement — all drugs for Stent Dislodgement →
Sponsor
DongGuk University
Who can join
20 and older, any sex, with Cholangitis or Post-ERCP Acute Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized controlled trial to determine the optimal placement duration of pancreatic duct stents (PDS) inserted during ERCP: 2 vs 4 weeks
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04691674
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Endoscopy
Trials testing the same drug.
- NCT07073300 — Endoscopic Findings in Patients Presented With Lower GIT Bleeding in Assiut University Hospitals, a Single-centre Study · not yet recruiting
- NCT07108751 — Association Between Gastroesophageal Reflux Disease (GERD) Severity and Dental Caries · completed
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT07043491 — Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy · recruiting
- NCT06637462 — A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer · NA · recruiting
Other recruiting trials for Cholangitis
Currently open trials in the same condition.
- NCT05750966 — Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis · NA · active not recruiting
- NCT05925309 — Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy · NA · recruiting
- NCT05061680 — Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI) · NA · recruiting
Other DongGuk University trials
Trials by the same sponsor.
- NCT07076628 — Respiratory Depression of Remimazolam vs. Propofol for Monitored Anesthesia Care · Phase 4 · completed
- NCT05999500 — The Effectiveness of Temple Stay in Irritable Bowel Syndrome · recruiting
- NCT06427109 — Omega-3 Fatty Acid and Colorectal Adenoma · completed
- NCT04072328 — Propofol vs. Midazolam With Propofol for Sedative Endoscopy in Patients With Previous Paradoxical Reaction to Midazolam · Phase 2 · completed
- NCT03868384 — The Effect of Home Blood Pressure Measurement on the Management of Hypertension · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04691674 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by DongGuk University
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04691674.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing